Guanfacine-13C,15N3

Guanfacine-13C,15N3 is the 13C and 15N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) [2][3][4].

Product Specifications

CAS Number

[1189924-28-4]

UNSPSC

12352005

Hazard Statement

H301, H312, H330, H410

Target

Adrenergic Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/guanfacine-13c-15n3.html

Solubility

10 mM in DMSO

Smiles

O=C([15NH][13C]([15NH2])=[15NH])CC1=C(Cl)C=CC=C1Cl

Molecular Formula

C8 13CH9Cl2 15N3O

Molecular Weight

250.07

Precautions

H301, H312, H330, H410

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Amy F T Arnsten, et al. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85 (1) :45-58. Epub 2012 Mar 29.|[3]P. A. Van Zwieten, et al. The pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol. 1983 15 (Suppl 4) : 455S–462S.|[4]Min Wang, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007 Apr 20129 (2) :397-410.